个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial.

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yang Zhenzhou[1,2,*1] ; Zhang Yan[3] ; Li Rongqing[4] ; Yisikandaer Abulimiti[5] ; Ren Biyong[6] ; Sun Jianguo[7] ; Li Jianjun[8] ; Chen Long[9] ; Zhao Ren[10] ; Zhang Juying[11] ; Xia Xuefeng[12] ; Liao Zhongxing[13,*2] ; Carbone David P[14,*3] ;
机构： [1]Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. [2]Cancer Center, Research Institute of Surgery, Daping Hospital, Chongqing, China. [3]Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [4]Department of Radiation Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, China. [5]Department of Radiotherapy of the Chest and Abdomen, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China. [6]Institute for Cancer Prevention and Treatment, Chongqing Sanxia Central Hospital, Chongqing, China. [7]Department of Medical Oncology, Xinqiao Hospital, Chongqing, China. [8]Department of Oncology, Southwest Hospital, Chongqing, China. [9]Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, China. [10]Department of Radiotherapy, General Hospital of Ningxia Medical University, Yinchuan, China. [11]Department of Epidemiology and Biostatistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China. [12]GenePlus-Beijing Institute, Peking University Medical Industrial Park, Zhongguancun Life Science Park, Beijing, China. [13]Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. [14]Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center, Columbus, USA.
出处：
DOI： 10.1093/neuonc/noaa281
ISSN：

关键词： Whole brain radiation therapy Erlotinib Brain metastases Non-small cell lung cancer Epidermal growth factor receptor

摘要：
Erlotinib combined with whole brain radiotherapy (WBRT) demonstrated a favorable objective response rate in a phase 2 single-arm trial of non-small cell lung cancer (NSCLC) patients with brain metastases. We assessed whether concurrent erlotinib with WBRT is safe and benefits patients in a phase 3, randomized trial. NSCLC patients with two or more brain metastases were enrolled and randomly assigned (1:1) to WBRT (n=115) or WBRT combined with erlotinib arms (n=109). The primary endpoint was intracranial progression-free survival (iPFS) and cognitive function (CF) was assessed by Mini-Mental State Examination (MMSE). A total of 224 patients from 10 centers across China were randomized to treatments. Median follow-up was 11.2 months. Median iPFS for WBRT concurrent erlotinib was 11.2 months versus 9.2 months for WBRT-alone (p=0.601). Median PFS and overall survival (OS) of combination group were 5.3 versus 4.0 months (p=0.825) and 12.9 versus 10.0 months (p=0.545), respectively, compared with WBRT-alone. In EGFR-mutant patients, iPFS (14.6 versus 12.8 months; p=0.164), PFS (8.8 versus 6.4 months; p=0.702) and OS (17.5 versus 16.9 months; p=0.221) were not significantly improved in combination group over WBRT-alone. Moreover, there were no significant differences in patients experiencing MMSE score change between the treatments. Concurrent erlotinib with WBRT didn't improve iPFS and excessive CF detriment either in the intent-to-treat (ITT) population or in EGFR-mutant patients compared with WBRT-alone, suggesting that while safe for patients already taking the drug, there is no justification for adding concurrent EGFR-TKI with WBRT for the treatment of brain metastases. © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

基金：
National Natural Science Foundation of China (Grant No. 81972851, 81472803, ZZ. Yang) and the Foundation and Frontier Research Project of Chongqing (Grant No. cstc2015jcyjBX0084, ZZ. Yang).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 临床神经病学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 临床神经病学 1 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 CLINICAL NEUROLOGY Q1 ONCOLOGY
最新[2023]版：
Q1 CLINICAL NEUROLOGY Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. [2]Cancer Center, Research Institute of Surgery, Daping Hospital, Chongqing, China. [*1]No.288 Tianwen Road, Nan’an District, Chongqing, China 400000
共同第一作者：
通讯作者：
通讯机构： [1]Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. [2]Cancer Center, Research Institute of Surgery, Daping Hospital, Chongqing, China. [13]Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. [14]Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Medical Center, Columbus, USA. [*1]No.288 Tianwen Road, Nan’an District, Chongqing, China 400000 [*2]Department of Radiation Oncology, Unit 1422, The University of Texas MD [*3]The Ohio State University Medical Center, 488 Biomedical Research Tower, 460 W. 12th Ave., Columbus, OH, 43210, USA
推荐引用方式(GB/T 7714)：
Yang Zhenzhou,Zhang Yan,Li Rongqing,et al.Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial.[J].NEURO-ONCOLOGY.2021,23(6):967-978.doi:10.1093/neuonc/noaa281.
APA：
Yang Zhenzhou,Zhang Yan,Li Rongqing,Yisikandaer Abulimiti,Ren Biyong...&Carbone David P.(2021).Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial..NEURO-ONCOLOGY,23,(6)
MLA：
Yang Zhenzhou,et al."Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial.".NEURO-ONCOLOGY 23..6(2021):967-978

相关文献

[1]Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer. [2]Stereotactic radiotherapy vs whole brain radiation therapy in EGFR mutated NSCLC: Results & reflections from the prematurely closed phase III HYBRID trial [3]Clinical Features of Brain Metastases in Small Cell Lung Cancer: an Implication for Hippocampal Sparing Whole Brain Radiation Therapy [4]Local Therapy for Oligoprogressive Disease in Advanced Staged Non-small Cell Lung Cancer Patients Harboring Epidermal Growth Factor Receptor Mutation [5]Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment [6]非小细胞肺癌患者表皮生长因子受体突变对靶向治疗的疗效影响及生存分析 [7]Clinical Benefit of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors Plus Radiotherapy for Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer: A Retrospective Analysis on Real World Data [8]Overexpression of CXCR4 promotes invasion and migration of non-small cell lung cancer via EGFR and MMP-9 [9]表皮生长因子受体-酪氨酸激酶抑制剂在治疗非小细胞肺癌方面的研究进展 [10]Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号